J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bonate, P.
Right arrow Articles by Russell, T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonate, P.
Right arrow Articles by Russell, T
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Assessment of QTc prolongation for non-cardiac-related drugs from a drug development perspective

PL Bonate and T Russell

It is increasingly likely that non-cardiac-related drugs will need to be routinely analyzed for their ability to prolong cardiac repolarization. This leads to potential problems for drug companies in general and statisticians in particular. A number of issues immediately arise in regard to answering the question, "Does drug X prolong cardiac repolarization?" These include identifying what is the desired outcome, what is the dependent variable, and what analysis method should be used. The purpose of this article is bring to to light some of the issues regarding the analysis of QTc data, the advantages and disadvantages of these analysis methods, and some general recommendations.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
S. Rohatagi, T. J. Carrothers, J. Kuwabara-Wagg, and T. Khariton
Is a Thorough QTc Study Necessary? The Role of Modeling and Simulation in Evaluating the QTc Prolongation Potential of Drugs
J. Clin. Pharmacol., November 1, 2009; 49(11): 1284 - 1296.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
G. Pirovano, D. B. Goodman, U. Halemane, C. Venetianer, M. A. Kirchin, and A. Spinazzi
Cardiac Electrophysiologic Monitoring after Injection of Gadobenate Dimeglumine versus Placebo in Healthy Volunteers and Patients with Cardiovascular Disease
Radiology, November 1, 2004; 233(2): 555 - 565.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
N. Sarapa, M. R. Britto, B. Cotton, S. R. Cox, S. F. Francom, N. Jin, E. D. Polasek, S. M. Sainati, S. L. Crosby-Sessoms, and J. C. Fleishaker
Valdecoxib, a COX-2-Specific Inhibitor, Does Not Affect Cardiac Repolarization
J. Clin. Pharmacol., September 1, 2003; 43(9): 974 - 982.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. L. Keefe
The Cardiotoxic Potential of the 5-HT3 Receptor Antagonist Antiemetics: Is There Cause for Concern?
Oncologist, February 1, 2002; 7(1): 65 - 72.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
P. Ball
Quinolone-induced QT interval prolongation: a not-so-unexpected class effect
J. Antimicrob. Chemother., May 1, 2000; 45(5): 557 - 559.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Clinical Pharmacology